Citation Impact
Citing Papers
2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines
2016 Standout
Nonproteasomal Targets of the Proteasome Inhibitors Bortezomib and Carfilzomib: a Link to Clinical Adverse Events
2011
Optimal strategies for the treatment of metastatic triple-negative breast cancer with currently approved agents
2012
EGFR Antagonists in Cancer Treatment
2008 Standout
Phosphorylation of Cell Surface Receptors: A Mechanism for Regulating Signal Transduction Pathways
1988 StandoutNobel
Perspectives on cancer therapy-induced mucosal injury
2004 Standout
Recovery from neutropenia can be predicted by the immature reticulocyte fraction several days before neutrophil recovery in autologous stem cell transplant recipients
2006
Use of Vancomycin-Containing Lock or Flush Solutions for Prevention of Bloodstream Infection Associated with Central Venous Access Devices: A Meta-Analysis of Prospective, Randomized Trials
2006
The resurgence of platinum-based cancer chemotherapy
2007 Standout
Angiogenesis and antiangiogenic therapy in hematologic malignancies
2006
Resistance mechanisms to cancer chemotherapy
2008
Signal transduction by receptors with tyrosine kinase activity
1990 Standout
Cardiotoxicity of anticancer treatments: what the cardiologist needs to know
2010
Efficacy of a vancomycin solution to prevent bacteremia associated with an indwelling central venous catheter in neutropenic and non-Neutropenic cancer patients
1997
Prophylactic antibiotics for preventing early central venous catheter Gram positive infections in oncology patients
2007
Intravascular-catheter-related infections
1998
Targeting RAS signalling pathways in cancer therapy
2003 Standout
Immunity, Inflammation, and Cancer
2010 Standout
β-Arrestin1 Interacts with the Catalytic Domain of the Tyrosine Kinase c-SRC
2000 StandoutNobel
The Multinational Association for Supportive Care in Cancer Risk Index: A Multinational Scoring System for Identifying Low-Risk Febrile Neutropenic Cancer Patients
2000
A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations
2010 Standout
Brown adipose tissue thermogenic adaptation requires Nrf1-mediated proteasomal activity
2018 StandoutNobel
Early Discharge of Low‐Risk Febrile Neutropenic Children and Adolescents with Cancer
1997
Treatment of Relapsed/Refractory Multiple Myeloma
2009
Minocycline‐Ethylenediaminetetraacetate Lock Solution for the Prevention of Implantable Port Infections in Children with Cancer
2003
Minocycline and Ethylenediaminetetraacetate for the Prevention of Recurrent Vascular Catheter Infections
1997
Removal of phosphorylation sites from the β2-adrenergic receptor delays onset of agonist-promoted desensitization
1988 StandoutNatureNobel
Molecular Genetic Pathways as Therapeutic Targets in Acute Myeloid Leukemia
2008
G Protein-coupled Receptors
1998 StandoutNobel
Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
2014 Standout
Treatment of Multiple Myeloma: A Comprehensive Review
2009
The C-terminus of the S. cerevisiae α-pheromone receptor mediates an adaptive response to pheromone
1988 StandoutNobel
Guidelines for the Prevention of Intravascular Catheter-related Infections
2011 Standout
Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine
1991 StandoutNature
An Intervention to Decrease Catheter-Related Bloodstream Infections in the ICU
2006 Standout
High response rate to bortezomib with or without dexamethasone in patients with relapsed or refractory multiple myeloma: results of a global phase 3b expanded access program
2008
Tumor Angiogenesis
2008 Standout
Factors influencing survival after relapse from acute lymphoblastic leukemia: a Children's Oncology Group study
2008
The cancer genome
2009 StandoutNature
Molecular Characterization of a Functional cDNA Encoding the Serotonin 1c Receptor
1988 StandoutScienceNobel
Circadian clock disruption improves the efficacy of chemotherapy through p73-mediated apoptosis
2011 StandoutNobel
Human insulin receptor and its relationship to the tyrosine kinase family of oncogenes
1985 StandoutNature
Dephosphorylation of the beta 2-adrenergic receptor and rhodopsin by latent phosphatase 2.
1988 StandoutNobel
Preventing Complications of Central Venous Catheterization
2003 Standout
Cerebrovascular accidents in sickle cell disease: rates and risk factors.
1998 Standout
Regulation of transmembrane signaling by receptor phosphorylation
1987 StandoutNobel
Bortezomib As Induction Before Autologous Transplantation, Followed by Lenalidomide As Consolidation-Maintenance in Untreated Multiple Myeloma Patients
2010
Receptor-specific desensitization with purified proteins. Kinase dependence and receptor specificity of beta-arrestin and arrestin in the beta 2-adrenergic receptor and rhodopsin systems.
1992 StandoutNobel
Identification of a Motif in the Carboxyl Terminus of β-Arrestin2 Responsible for Activation of JNK3
2001 StandoutNobel
Randomized, Double-Blind Trial of an Antibiotic-Lock Technique for Prevention of Gram-Positive Central Venous Catheter-Related Infection in Neutropenic Patients with Cancer
1999
Clinical Practice Guideline for the Use of Antimicrobial Agents in Neutropenic Patients with Cancer: 2010 Update by the Infectious Diseases Society of America
2011 Standout
beta-Adrenergic receptor kinase. Activity of partial agonists for stimulation of adenylate cyclase correlates with ability to promote receptor phosphorylation.
1988 StandoutNobel
Identification of residues in the nucleotide binding site of the epidermal growth factor receptor/kinase.
1985 StandoutNobel
Outpatient treatment of fever and neutropenia for low risk pediatric cancer patients
1999
Autophosphorylation and protein kinase C phosphorylation of the epidermal growth factor receptor. Effect on tyrosine kinase activity and ligand binding affinity.
1985
Bortezomib Plus Dexamethasone Is Superior to Vincristine Plus Doxorubicin Plus Dexamethasone As Induction Treatment Prior to Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: Results of the IFM 2005-01 Phase III Trial
2010
2002 Guidelines for the Use of Antimicrobial Agents in Neutropenic Patients with Cancer
2002 Standout
β-Adrenergic Receptor Kinase-2 and β-Arrestin-2 as Mediators of Odorant-Induced Desensitization
1993 StandoutScienceNobel
Functional activity and regulation of human beta 2-adrenergic receptors expressed in Xenopus oocytes.
1987 StandoutNobel
Adrenergic receptors. Models for the study of receptors coupled to guanine nucleotide regulatory proteins.
1988 StandoutNobel
Beta-arrestin2, a novel member of the arrestin/beta-arrestin gene family.
1992 StandoutNobel
cis -Diammine(pyridine)chloroplatinum(II), a monofunctional platinum(II) antitumor agent: Uptake, structure, function, and prospects
2008 StandoutNobel
Consenso Manejo racional del paciente con cáncer, neutropenia y fiebre: Rational approach towards the patient with cancer, fever and neutropenia
2005
Phosphorylation Sites on Two Domains of the β2-Adrenergic Receptor Are Involved in Distinct Pathways of Receptor Desensitization
1989 StandoutNobel
A Vancomycin-Heparin Lock Solution for Prevention of Nosocomial Bloodstream Infection in Critically Ill Neonates With Peripherally Inserted Central Venous Catheters: A Prospective, Randomized Trial
2005
Cloning, expression, and chromosomal localization of beta-adrenergic receptor kinase 2. A new member of the receptor kinase family
1991 StandoutNobel
Growth factors: The epidermal growth factor receptor gene and its product
1984 Nature
Cloning, Sequencing, and Expression of the Gene Coding for the Human Platelet α 2 -Adrenergic Receptor
1987 StandoutScienceNobel
Prevention of Central Venous Catheter–Related Infections and Thrombotic Events in Immunocompromised Children by the Use of Vancomycin/Ciprofloxacin/Heparin Flush Solution: A Randomized, Multicenter, Double-Blind Trial
2000
“Low-Risk” Prediction Rule for Pediatric Oncology Patients Presenting With Fever and Neutropenia
2000
Emerging Targets in Photopharmacology
2016 StandoutNobel
Multiple Myeloma
2011 Standout
A beta-adrenergic receptor kinase-like enzyme is involved in olfactory signal termination.
1993 StandoutNobel
Circadian control of XPA and excision repair of cisplatin-DNA damage by cryptochrome and HERC2 ubiquitin ligase
2010 StandoutNobel
Chemotherapy triggers HIF-1–dependent glutathione synthesis and copper chelation that induces the breast cancer stem cell phenotype
2015 StandoutNobel
Alteration of epidermal growth factor receptor activity by mutation of its primary carboxyl-terminal site of tyrosine self-phosphorylation.
1988
Photopharmacology: Beyond Proof of Principle
2014 StandoutNobel
G-protein-coupled Receptor (GPCR) Kinase Phosphorylation and β-Arrestin Recruitment Regulate the Constitutive Signaling Activity of the Human Cytomegalovirus US28 GPCR
2003 StandoutNobel
Works of Wayne Rackoff being referenced
Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer
2004
Central Venous Catheter Use and the Risk of Infection in Children With Acute Lymphoblastic Leukemia
1999
A randomized, controlled trial of the efficacy of a heparin and vancomycin solution in preventing central venous catheter infections in children
1995
Neurologic events after partial exchange transfusion for priapism in sickle cell disease
1992
High Dose Cyclophosphamide with Carboplatin: A Tolerable Regimen Suitable for Dose Intensification in Children with Solid Tumors
1997
Predicting the risk of bacteremia in childen with fever and neutropenia.
1996
Reply to: Correction: Heparin-vancomycin solution to prevent central venous catheter infections
1995
Pegylated Liposomal Doxorubicin Plus Docetaxel Significantly Improves Time to Progression Without Additive Cardiotoxicity Compared With Docetaxel Monotherapy in Patients With Advanced Breast Cancer Previously Treated With Neoadjuvant-Adjuvant Anthracycline Therapy: Results From a Randomized Phase III Study
2009
Efficacy of the farnesyl transferase inhibitor R115777 in chronic myeloid leukemia and other hematologic malignancies
2003
A phase 2 study of the oral farnesyltransferase inhibitor tipifarnib in patients with refractory or relapsed acute myeloid leukemia
2007
Phosphorylation of the hepatic EGF receptor with cAMP-dependent protein kinase
1984
Randomized Phase III Study of Pegylated Liposomal Doxorubicin Plus Bortezomib Compared With Bortezomib Alone in Relapsed or Refractory Multiple Myeloma: Combination Therapy Improves Time to Progression
2007